te Gland Pharma gets USFDA nod for generic injectable | Zee Business

Gland Pharma gets USFDA nod for generic injectable

Gland Pharma on Wednesday said it has received approval from the US health regulator to market a generic product used to raise blood pressure.

Gland Pharma gets USFDA nod for generic injectable
The company believes that it is the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity, it added. Image Source: glandpharma.com

Gland Pharma on Wednesday said it has received approval from the US health regulator to market a generic product used to raise blood pressure.

The Hyderabad-based company has received tentative approval from the US Food and Drug Administration (USFDA) for Angiotensin II Injection, 2.5 mg/mL Single Dose Vial, it said in a regulatory filing.

The company believes that it is the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity, it added.

TRENDING NOW

According to IQVIA data, Angiotensin II Injection (2.5 mg/mL Single Dose Vial) has US sales of around USD 38 million for twelve months ended in September 2023.

Shares of drug firm were trading 0.68 per cent down at Rs 1,613.35 apiece on the BSE.

 

Written By: PTI
Updated: Wed, Nov 15, 2023
03:43 pm
PTI
RELATED NEWS
Gland Pharma stock gets a shot in the arm after firm's US business picked up in Q2, brokerages increase target price Gland Pharma stock gets a shot in the arm after firm's US business picked up in Q2, brokerages increase target price
Gland Pharma shares soar 20% after upbeat Q1 result and strong future outlook Gland Pharma shares soar 20% after upbeat Q1 result and strong future outlook

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x